Martin Landray

Martin Landray   (epidemiologist, Big Pharma/lobbyist)
Born	1968
Nationality	UK
Alma mater	Abingdon School, University of Birmingham
Parents	• Bob Landray • Margaret Bray.
Interests	• hydroxychloroquine • Rigged science • Bill & Melinda Gates Foundation • Wellcome Trust
UK epidemiologist working for the Bill & Melinda Gates Foundation who used potentially deadly dose in trial of COVID-drug hydroxychloroquine.

Sir Martin Jonathan Landray is a British physician, epidemiologist and data scientist who serves as a Professor of Medicine & Epidemiology at the University of Oxford.

Landray is paid by the Wellcome Trust and the Bill & Melinda Gates Foundation for designing, conducting and analysing large-scale randomised control trials; including practice-changing international trials.

In a June 2020 he led trial into hydroxychloroquine as a theruapetic drug for Covid-19. In the trial, they at first used more than four or five times the European Medicines Agency’s maximum authorized dose of hydroxychloroquine. The drug can be very dangerous if taken at very high dosage. Later, other researchers were not able to gain access to the original database indicating at which point in time along the therapeutic course the participants died.

The result of the trial, "no beneficial effect of hydroxychloroquine in patients hospitalised with COVID-19" also aligns with the opinion of his donors, which pushed for a vaccine as the only solution.

Career

He was educated at Abingdon School in Abingdon-on-Thames, Oxfordshire, from 1982 until 1987. After Abingdon he went on to study medicine at the University of Birmingham, returning later for specialist training in Clinical Pharmacology & Therapeutics, and General Internal Medicine.

Career

He leads the Good Clinical Trial Collaborative, established by Wellcome Trust, Bill & Melinda Gates Foundation, and African Academy of Sciences which seeks to develop and promote the adoption of new international guidelines for randomised control trials. He was previously one of the leaders of the Clinical Trial Transformation Initiative's risk-based monitoring, quality-by-design, and mobile clinical trial projects.

He is an advocate of streamlined approaches to clinical trial design, delivery and regulation "as a means to improve healthcare". This means less testing on medicines before they are released, and is conveniently exactly the same position as his patrons the Bill & Melinda Gates Foundation and the pharma industry.

Landray previously led the health informatics team that enabled the collection and management of data for the UK Biobank on over half a million people. He is founding director and chair of NHS DigiTrials, the Health Data Research Hub for Clinical Trials hosted by NHS Digital, and leads the clinical trials theme for Health Data Research UK.

In 2021, Landray was appointed to the Pandemic Preparedness Partnership (PPP), a group chaired by Patrick Vallance to advise the G7 presidency held by the government of Prime Minister Boris Johnson.

He was knighted in the 2021 Birthday Honours for services to public health and science.

RECOVERY Trial

Toegether with Professor Peter Horby, Landray led a June 2020 University of Oxford trial (RECOVERY Trial) into hydroxychloroquine as a therapeutic drug for Covid-19. On the first day of the trial, they used more than four or five times the European Medicines Agency’s maximum authorised dose of hydroxychloroquine.

Hydroxychloroquine may be an adjunct of suicide if taken at very high dosage. In the RECOVERY Trial, the mortality rate was high, much higher than in other trials. They then modified the evaluation criteria. Later, other researchers were not able to gain access to the original database indicating at which point in time along the therapeutic course the participants died.

As French professor Christian Perronne pointed out:

I saw that he didn’t understand anything about infectious diseases, about anti-infection drugs, and [yet] he was the leader of an international trial. International, because French scientists also participated in that trial. So, for me, it was something so terrible. I couldn’t imagine that experts could do this kind of trial, and I couldn’t imagine that ethics committees could give authorisation for this kind of trial, with dosages which were very dangerous.

Many thanks to our Patrons who cover ~2/3 of our hosting bill. Please join them if you can.